Document is current
Any future updates will be listed below
-
Authors
Li, Jiazhi https://orcid.org/0000-0001-5984-9920
Wang, Longfei
Hahn, Quentin https://orcid.org/0000-0003-3510-8364
Nowak, Radosław P. https://orcid.org/0000-0002-0605-0071
Viennet, Thibault https://orcid.org/0000-0001-5349-0179
Orellana, Esteban A. https://orcid.org/0000-0003-4369-9416
Roy Burman, Shourya S. https://orcid.org/0000-0001-9274-9104
Yue, Hong
Hunkeler, Moritz https://orcid.org/0000-0003-0246-1188
Fontana, Pietro https://orcid.org/0000-0003-3215-3784
Wu, Hao
Arthanari, Haribabu
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
Gregory, Richard I. https://orcid.org/0000-0001-8090-8673
- License Information
-
More Information
Article History
Received: 22 May 2022
Accepted: 16 November 2022
First Online: 4 January 2023
Competing interests
: R.I.G. is a co-founder and scientific advisory board (SAB) member of 28/7 Therapeutics and Theonys. E.S.F. is a founder, SAB member and equity holder in Civetta Therapeutics, Lighthorse Therapeutics, Neomorph, Inc. (board of directors) and Proximity Therapeutics. E.S.F. is a SAB member and equity holder in Avilar Therapeutics and Photys Therapeutics. E.S.F. is also a consultant to Novartis, Sanofi, EcoR1 capital, Avilar and Deerfield. The Fischer laboratory receives or has received research funding from Astellas, Novartis, Voronoi, Interline, Ajax and Deerfield. The rest of the authors declare no competing interests.
